Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.

PubWeight™: 3.10‹?› | Rank: Top 1%

🔗 View Article (PMID 22326922)

Published in Lancet Oncol on February 10, 2012


Alfons J M van den Eertwegh1, Jurjen Versluis, H Pieter van den Berg, Saskia J A M Santegoets, R Jeroen A van Moorselaar, Tim M van der Sluis, Helen E Gall, Thomas C Harding, Karin Jooss, Israel Lowy, Herbert M Pinedo, Rik J Scheper, Anita G M Stam, B Mary E von Blomberg, Tanja D de Gruijl, Kristen Hege, Natalie Sacks, Winald R Gerritsen

Author Affiliations

1: Department of Medical Oncology, VU University Medical Centre, Amsterdam, Netherlands.

Associated clinical trials:

Phase 1 Trial of Ipilimumab and GVAX in Patients With Metastatic Castration-resistant Prostate Cancer | NCT01510288

Articles citing this

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol (2014) 5.89

Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer. J Immunother (2013) 2.80

Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann Oncol (2013) 2.35

Dendritic-cell-based therapeutic cancer vaccines. Immunity (2013) 2.29

Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. JAMA (2014) 2.13

What have we learned from cancer immunotherapy in the last 3 years? J Transl Med (2014) 1.52

Trial watch: Monoclonal antibodies in cancer therapy. Oncoimmunology (2013) 1.41

Vaccines for established cancer: overcoming the challenges posed by immune evasion. Nat Rev Cancer (2016) 1.31

Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells. Immunity (2016) 1.21

An update on vaccine therapy and other immunotherapeutic approaches for glioblastoma. Expert Rev Vaccines (2013) 1.08

Immunotherapy advances for glioblastoma. Neuro Oncol (2014) 1.07

Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. Oncoimmunology (2015) 1.06

Immunomodulatory therapy for melanoma: ipilimumab and beyond. Clin Dermatol (2013) 1.04

Therapeutic cancer vaccines: past, present, and future. Adv Cancer Res (2013) 0.99

Prostate cancer vaccines: Update on clinical development. Oncoimmunology (2013) 0.98

Trial Watch: Immunostimulatory cytokines. Oncoimmunology (2013) 0.96

Skin-resident antigen-presenting cells: instruction manual for vaccine development. Front Immunol (2013) 0.94

Cancer immunotherapy: a paradigm shift for prostate cancer treatment. Nat Rev Urol (2012) 0.93

Sustained complete response to CTLA-4 blockade in a patient with metastatic, castration-resistant prostate cancer. Cancer Immunol Res (2014) 0.93

Sequencing CTLA-4 blockade with cell-based immunotherapy for prostate cancer. J Transl Med (2013) 0.93

Molecular Pathways: Activating T Cells after Cancer Cell Phagocytosis from Blockade of CD47 "Don't Eat Me" Signals. Clin Cancer Res (2015) 0.92

Immunotherapy for prostate cancer: lessons from responses to tumor-associated antigens. Front Immunol (2014) 0.92

Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors. Epigenetics (2013) 0.92

Exploiting synergy: immune-based combinations in the treatment of prostate cancer. Front Oncol (2014) 0.91

Metastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapy. Oncogene (2013) 0.91

Immunotherapy for prostate cancer: recent developments and future challenges. Cancer Metastasis Rev (2014) 0.90

Clinical Implications of Co-Inhibitory Molecule Expression in the Tumor Microenvironment for DC Vaccination: A Game of Stop and Go. Front Immunol (2013) 0.90

Management of low risk prostate cancer-active surveillance and focal therapy. Nat Rev Clin Oncol (2014) 0.88

A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer. Cancer Immunol Res (2014) 0.87

Phase II trial of a GM-CSF-producing and CD40L-expressing bystander cell line combined with an allogeneic tumor cell-based vaccine for refractory lung adenocarcinoma. J Immunother (2013) 0.87

Allogeneic tumor cell vaccines: the promise and limitations in clinical trials. Hum Vaccin Immunother (2013) 0.87

Therapeutic vaccines as a promising treatment modality against prostate cancer: rationale and recent advances. Ther Adv Vaccines (2014) 0.86

Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab. J Immunother Cancer (2014) 0.86

Blocking immune checkpoints in prostate, kidney, and urothelial cancer: An overview. Urol Oncol (2016) 0.86

Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications. Asian J Androl (2014) 0.84

Demystifying immunotherapy in prostate cancer: understanding current and future treatment strategies. Cancer J (2013) 0.84

Novel immune checkpoint blocker approved for the treatment of advanced melanoma. Oncoimmunology (2014) 0.84

Implementing combinatorial immunotherapeutic regimens against cancer: The concept of immunological conditioning. Oncoimmunology (2014) 0.84

Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy. JAAD Case Rep (2016) 0.83

Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience. Oncogene (2015) 0.83

Recent advances in therapeutic cancer vaccines. Cancer Biother Radiopharm (2012) 0.83

Inhibitory receptors as targets for cancer immunotherapy. Eur J Immunol (2015) 0.83

Beyond the Immune Suppression: The Immunotherapy in Prostate Cancer. Biomed Res Int (2015) 0.82

Proposed mechanisms of action for prostate cancer vaccines. Nat Rev Urol (2013) 0.82

From bench to bedside: immunotherapy for prostate cancer. Biomed Res Int (2014) 0.81

Castration-resistant prostate cancer: potential targets and therapies. Biologics (2012) 0.81

Evolving Concepts: Immunity in Oncology from Targets to Treatments. J Oncol (2015) 0.81

Preoperative therapy for localized prostate cancer: a comprehensive overview. Maturitas (2012) 0.81

Prostate cancer: combination of vaccine plus ipilimumab--safety and toxicity. Nat Rev Urol (2012) 0.81

Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors. Viruses (2015) 0.80

Development of thyroglobulin antibodies after GVAX immunotherapy is associated with prolonged survival. Int J Cancer (2014) 0.80

Immune regulation of bone metastasis. Bonekey Rep (2014) 0.80

Safety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting. J Transl Med (2015) 0.80

Immune response to cancer therapy: mounting an effective antitumor response and mechanisms of resistance. Trends Cancer (2015) 0.79

Immune checkpoint inhibitor therapy associated hypophysitis. Clin Med Insights Endocrinol Diabetes (2015) 0.79

Ipilimumab-Induced Gastrointestinal Toxicities: A Management Algorithm. Dig Dis Sci (2016) 0.79

Combination immunotherapy with prostate GVAX and ipilimumab: safety and toxicity. Immunotherapy (2012) 0.79

Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors. Vaccines (Basel) (2016) 0.78

Combining active immunotherapy with immune checkpoint blockade for the treatment of advanced prostate cancer. Asian J Androl (2012) 0.78

The Rapid Emergence of Novel Therapeutics in Advanced Malignant Melanoma. Dermatol Ther (Heidelb) (2015) 0.78

Whole Cell Therapeutic Vaccine Modified With Hyper-IL6 for Combinational Treatment of Nonresected Advanced Melanoma. Medicine (Baltimore) (2015) 0.78

Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate Cancer. Cancer Immunol Res (2016) 0.78

Personalized peptide vaccines and their relation to other therapies in urological cancer. Nat Rev Urol (2017) 0.77

The Nuclear Orphan Receptor NR2F6 Is a Central Checkpoint for Cancer Immune Surveillance. Cell Rep (2015) 0.77

Emerging options for the treatment of melanoma - focus on ipilimumab. Immunotargets Ther (2014) 0.77

Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy. Front Oncol (2016) 0.77

Next-generation cancer vaccine approaches: integrating lessons learned from current successes with promising biotechnologic advances. J Natl Compr Canc Netw (2013) 0.77

The Promise of Preventive Cancer Vaccines. Vaccines (Basel) (2015) 0.77

The Rationale for Optimal Combination Therapy With Sipuleucel-T for Patients With Castration-resistant Prostate Cancer. Rev Urol (2014) 0.77

Immunotherapy for prostate cancer enters its golden age. Clin Med Insights Oncol (2012) 0.77

In vivo imaging of therapy-induced anti-cancer immune responses in humans. Cell Mol Life Sci (2012) 0.76

Antitumor vaccination of prostate cancer patients elicits PD-1/PD-L1 regulated antigen-specific immune responses. Oncoimmunology (2016) 0.76

Intensifying tumour immunity through combination therapy. Lancet Oncol (2012) 0.76

Immune Therapy for Prostate Cancer. Cancer J (2016) 0.76

Immunotherapy and immune evasion in prostate cancer. Cancers (Basel) (2013) 0.76

Active and passive immunization for cancer. Hum Vaccin Immunother (2014) 0.76

Immune Checkpoint Inhibitors and Prostate Cancer: A New Frontier? Oncol Rev (2016) 0.76

Host controls of HIV broadly neutralizing antibody development. Immunol Rev (2017) 0.76

Immunotherapy in genitourinary malignancies. Curr Opin Urol (2016) 0.75

Is there a role for immune checkpoint blockade with ipilimumab in prostate cancer? Cancer Med (2013) 0.75

Surface engineering tumor cells with adjuvant-loaded particles for use as cancer vaccines. J Control Release (2017) 0.75

Improved efficacy of mitoxantrone in patients with castration-resistant prostate cancer after vaccination with GM-CSF-transduced allogeneic prostate cancer cells. Oncoimmunology (2015) 0.75

Diarrhoea in a patient with metastatic melanoma: Ipilimumab ileocolitis treated with infliximab. World J Gastrointest Pharmacol Ther (2013) 0.75

Adding fuel to the fire: immunogenic intensification. Hum Vaccin Immunother (2014) 0.75

Don't run before you can walk. Nat Rev Urol (2012) 0.75

Thermal Ablative Therapies and Immune Checkpoint Modulation: Can Locoregional Approaches Effect a Systemic Response? Gastroenterol Res Pract (2016) 0.75

Emerging treatments in management of prostate cancer: biomarker validation and endpoints for immunotherapy clinical trial design. Immunotargets Ther (2013) 0.75

DNA vaccines for prostate cancer. Pharmacol Ther (2017) 0.75

In Vivo Expansion of Melanoma-Specific T Cells Using Microneedle Arrays Coated with Immune-Polyelectrolyte Multilayers. ACS Biomater Sci Eng (2016) 0.75

Prostate cancer immunotherapy, particularly in combination with androgen deprivation or radiation treatment. Customized pharmacogenomic approaches to overcome immunotherapy cancer resistance. G Chir (2017) 0.75

Wilms tumor 1 peptide vaccination after hematopoietic stem cell transplant in leukemia patients. Stem Cell Investig (2016) 0.75

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma. J Immunother Cancer (2016) 0.75

Immunotherapy in metastatic prostate cancer. Indian J Urol (2016) 0.75

Immunotherapy: shifting the balance of cell-mediated immunity and suppression in human prostate cancer. Cancers (Basel) (2012) 0.75

A Perspective of Immunotherapy for Prostate Cancer. Cancers (Basel) (2016) 0.75

The best of both worlds - managing the cancer, saving the bone. Nat Rev Endocrinol (2015) 0.75

Novel GM-CSF-based vaccines: One small step in GM-CSF gene optimization, one giant leap for human vaccines. Hum Vaccin Immunother (2016) 0.75

Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment. J Natl Cancer Inst (2017) 0.75

Articles by these authors

Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 17.53

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol (2010) 17.13

Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med (2012) 15.69

Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol (2006) 7.40

Functional delivery of viral miRNAs via exosomes. Proc Natl Acad Sci U S A (2010) 6.72

Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol (2008) 5.21

Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A (2008) 4.43

Stable antibody expression at therapeutic levels using the 2A peptide. Nat Biotechnol (2005) 4.14

Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood (2008) 3.65

Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer (2003) 3.47

Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother (2007) 3.32

Lower testosterone levels with luteinizing hormone-releasing hormone agonist therapy than with surgical castration: new insights attained by mass spectrometry. J Urol (2012) 3.28

Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother (2010) 3.06

Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors. Clin Cancer Res (2009) 2.97

A clinical development paradigm for cancer vaccines and related biologics. J Immunother (2007) 2.97

Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discov (2013) 2.93

A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res (2002) 2.86

The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci U S A (2002) 2.79

A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res (2007) 2.71

Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer (2007) 2.68

Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. Clin Cancer Res (2008) 2.67

Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J Clin Oncol (2002) 2.55

Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res (2005) 2.48

Low levels of circulating invariant natural killer T cells predict poor clinical outcome in patients with head and neck squamous cell carcinoma. J Clin Oncol (2007) 2.47

Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. J Natl Cancer Inst (2004) 2.41

Disruption of Abcc6 in the mouse: novel insight in the pathogenesis of pseudoxanthoma elasticum. Hum Mol Genet (2005) 2.36

Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32

Accuracy of serologic tests and HLA-DQ typing for diagnosing celiac disease. Ann Intern Med (2007) 2.26

A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. Clin Cancer Res (2007) 2.24

External beam radiation therapy followed by interstitial radiotherapy with iridium-192 for solitary bladder tumours: results of 111 treated patients. Eur Urol (2008) 2.13

Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters. Infect Immun (2006) 2.09

Cladribine therapy in refractory celiac disease with aberrant T cells. Clin Gastroenterol Hepatol (2006) 2.04

Mrp4 confers resistance to topotecan and protects the brain from chemotherapy. Mol Cell Biol (2004) 1.93

Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine). Drug Resist Updat (2002) 1.91

Positron emission tomography using 2-deoxy-2-[18F]-fluoro-D-glucose for response monitoring in locally advanced gastroesophageal cancer; a comparison of different analytical methods. Mol Imaging Biol (2003) 1.86

Serum anti-toxin B antibody correlates with protection from recurrent Clostridium difficile infection (CDI). Vaccine (2009) 1.85

MRP6 (ABCC6) detection in normal human tissues and tumors. Lab Invest (2002) 1.79

Virus-mediated transduction of murine retina with adeno-associated virus: effects of viral capsid and genome size. J Virol (2002) 1.77

Characterization of four conventional dendritic cell subsets in human skin-draining lymph nodes in relation to T-cell activation. Blood (2011) 1.76

CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood (2008) 1.74

Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor. Cancer Res (2005) 1.73

Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res (2007) 1.71

Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients. J Clin Oncol (2005) 1.70

Immune activation driven by CTLA-4 blockade augments viral replication at mucosal sites in simian immunodeficiency virus infection. J Immunol (2008) 1.69

Frequent expression of the multi-drug resistance-associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP-21 monoclonal antibody in paraffin-embedded material. J Pathol (2002) 1.64

Pharmacological induction of interferon type I activity following treatment with rituximab determines clinical response in rheumatoid arthritis. Ann Rheum Dis (2011) 1.62

Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy. Clin Cancer Res (2006) 1.60

Sexual dysfunction in 1,274 European men suffering from lower urinary tract symptoms. J Urol (2003) 1.58

Nutritional management of the gluten-free diet in young people with celiac disease in The Netherlands. J Pediatr Gastroenterol Nutr (2006) 1.52

Selective decrease in circulating V alpha 24+V beta 11+ NKT cells during HIV type 1 infection. J Immunol (2002) 1.52

Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity. Mol Cancer Ther (2002) 1.52

Prostanoids play a major role in the primary tumor-induced inhibition of dendritic cell differentiation. J Immunol (2002) 1.49

Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res (2009) 1.48

Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer (2008) 1.48

CTLA-4 blockade decreases TGF-beta, IDO, and viral RNA expression in tissues of SIVmac251-infected macaques. Blood (2006) 1.45

Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice. J Infect Dis (2005) 1.44

Evidence for subcomplexes in the Fanconi anemia pathway. Blood (2006) 1.43

Exploring dendritic cell based vaccines targeting survivin for the treatment of head and neck cancer patients. J Transl Med (2013) 1.40

Vaults: a ribonucleoprotein particle involved in drug resistance? Oncogene (2003) 1.39

Peripheral blood IFN-gamma-secreting Valpha24+Vbeta11+ NKT cell numbers are decreased in cancer patients independent of tumor type or tumor load. Int J Cancer (2005) 1.39

Prophylaxis and therapy of inhalational anthrax by a novel monoclonal antibody to protective antigen that mimics vaccine-induced immunity. Infect Immun (2006) 1.38

ATP-binding cassette (ABC) transporters in normal and pathological lung. Respir Res (2005) 1.37

Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer. Urol Oncol (2006) 1.36

Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival. Clin Cancer Res (2008) 1.36

Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542. Antimicrob Agents Chemother (2004) 1.34

Clinical experience with α-galactosylceramide (KRN7000) in patients with advanced cancer and chronic hepatitis B/C infection. Clin Immunol (2010) 1.34

Autologous hematopoietic stem cell transplantation in refractory celiac disease with aberrant T cells. Blood (2006) 1.31

CD4(+)CD25hi regulatory T-cell frequency correlates with persistence of human papillomavirus type 16 and T helper cell responses in patients with cervical intraepithelial neoplasia. Int J Cancer (2007) 1.31

Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. Cancer Res (2002) 1.30

Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment. Cancer (2013) 1.27

An antibody delivery system for regulated expression of therapeutic levels of monoclonal antibodies in vivo. Mol Ther (2007) 1.26

Flow cytometric determination of aberrant intra-epithelial lymphocytes predicts T-cell lymphoma development more accurately than T-cell clonality analysis in Refractory Celiac Disease. Clin Immunol (2007) 1.26

Local administration of PF-3512676 CpG-B instigates tumor-specific CD8+ T-cell reactivity in melanoma patients. Clin Cancer Res (2008) 1.24

Measurements and clinical consequences of prostate motion during a radiotherapy fraction. Int J Radiat Oncol Biol Phys (2002) 1.23

MUTZ-3, a human cell line model for the cytokine-induced differentiation of dendritic cells from CD34+ precursors. Blood (2002) 1.21